《新股消息》據報(方土方)博醫療獲批港上市 籌3億美元
據《路透社》旗下《IFR》引述消息指,內地肺病醫療公司(方土方)博醫療(Broncus)獲批上市,籌集3億美元。高盛和海通國際為聯席保薦人。
據其早前上載的初步招股文件顯示,公司成立於2012年,為介入性肺病學領域的開拓者,在中國和全球範圍內提供創新型肺部疾病解決方案,共有476項專利和專利申請。
截至2020年度,公司收入按年下跌60%至326萬美元,年內虧損淨額擴大至4,879萬美元,2019年同期虧損為3,255萬美元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.